Skip to main
HUM
HUM logo

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 16 analyst ratings
Hold
Strong Buy 6%
Buy 31%
Hold 63%
Sell 0%
Strong Sell 0%

Bulls say

Humana's revised 2025 earnings per share (EPS) estimate has been increased to $17.06, reflecting positive second-quarter results and updated guidance, which indicates strong financial performance. Anticipated year-over-year earnings growth for 2027 is expected due to the implementation of margin initiatives, despite stable assumptions regarding Stars program bonus payments. Furthermore, Humana's superior Medicare Advantage star rating enhances its competitive position in the evolving regulatory landscape, reflecting a solid foundation for future growth.

Bears say

Humana's management anticipates a slight decline in earnings per share (EPS) for 2026 compared to 2025 due to ongoing pressures related to Star ratings, despite margin improvement efforts. Key downside risks include heightened competition in Medicare Advantage, insufficient reimbursement rates, decreasing membership in prescription drug plans, lower Star ratings, and sluggish growth in healthcare services, all contributing to a challenging outlook. Furthermore, the firm's projections suggest a potential 10% shortfall in 2027 EPS estimates, driven by increased investments necessary for Star rating recovery efforts.

Humana (HUM) has been analyzed by 16 analysts, with a consensus rating of Hold. 6% of analysts recommend a Strong Buy, 31% recommend Buy, 63% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 16 analysts, Humana (HUM) has a Hold consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $298.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $298.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.